Brawn Rare Disease, in collaboration with Vitaflo International Ltd, holds the distribution rights for Food for Special Medical Purposes (FSMP) products in India for patients suffering from rare IEM conditions, such as Tyrosinemia Type 1 and Phenylketonuria (PKU).
Parents and medical professionals seeking emergency life-saving diets can reach out to:
The Central Government has granted full exemption from basic customs duty on all medicines and Food for Special Medical Purposes (FSMP) imported for personal use in treating rare diseases listed under the National Policy for Rare Diseases 2021.
5-Aark Pharmaceuticals Private Limited
Breakthrough Rare Disease Medicines Accessible in India
https://aarkpharma.com/breakthrough-medicines-in-rare-disease-treatment/
In India, Sanofi (formerly Genzyme) and Takeda are the primary pharmaceutical companies providing Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders (LSDs).
While other global pharmaceutical companies, such as AstraZeneca and Roche, operate within the rare disease sector in India, their current focus remains on alternative modalities (such as oral therapies or biologics for Spinal Muscular Atrophy and rare blood disorders) rather than traditional ERT.
|
Company |
Key ERT Products |
Rare Diseases Covered |
|
Sanofi (Sanofi Genzyme) |
Cerezyme, Fabrazyme, Myozyme, Aldurazyme, Nexviazyme |
Gaucher Disease, Fabry Disease, Pompe Disease, MPS I, ASMD |
|
Takeda Pharmaceuticals |
Vpriv, Elaprase, Replagal |
Gaucher Disease, Hunter Syndrome (MPS II), Fabry Disease |